216 related articles for article (PubMed ID: 28749580)
1. Dopamine Transporter Neuroimaging as an Enrichment Biomarker in Early Parkinson's Disease Clinical Trials: A Disease Progression Modeling Analysis.
Conrado DJ; Nicholas T; Tsai K; Macha S; Sinha V; Stone J; Corrigan B; Bani M; Muglia P; Watson IA; Kern VD; Sheveleva E; Marek K; Stephenson DT; Romero K;
Clin Transl Sci; 2018 Jan; 11(1):63-70. PubMed ID: 28749580
[TBL] [Abstract][Full Text] [Related]
2. The Qualification of an Enrichment Biomarker for Clinical Trials Targeting Early Stages of Parkinson's Disease.
Stephenson D; Hill D; Cedarbaum JM; Tome M; Vamvakas S; Romero K; Conrado DJ; Dexter DT; Seibyl J; Jennings D; Nicholas T; Matthews D; Xie Z; Imam S; Maguire P; Russell D; Gordon MF; Stebbins GT; Somer E; Gallagher J; Roach A; Basseches P; Grosset D; Marek K;
J Parkinsons Dis; 2019; 9(3):553-563. PubMed ID: 31306141
[TBL] [Abstract][Full Text] [Related]
3. Molecular Neuroimaging of the Dopamine Transporter as a Patient Enrichment Biomarker for Clinical Trials for Early Parkinson's Disease.
Romero K; Conrado D; Burton J; Nicholas T; Sinha V; Macha S; Ahamadi M; Cedarbaum J; Seibyl J; Marek K; Basseches P; Hill D; Somer E; Gallagher J; Dexter DT; Roach A; Stephenson D; ;
Clin Transl Sci; 2019 May; 12(3):240-246. PubMed ID: 30706986
[TBL] [Abstract][Full Text] [Related]
4. Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study.
Simuni T; Uribe L; Cho HR; Caspell-Garcia C; Coffey CS; Siderowf A; Trojanowski JQ; Shaw LM; Seibyl J; Singleton A; Toga AW; Galasko D; Foroud T; Tosun D; Poston K; Weintraub D; Mollenhauer B; Tanner CM; Kieburtz K; Chahine LM; Reimer A; Hutten SJ; Bressman S; Marek K;
Lancet Neurol; 2020 Jan; 19(1):71-80. PubMed ID: 31678032
[TBL] [Abstract][Full Text] [Related]
5. Genome-wide variant by serum urate interaction in Parkinson's disease.
Nazeri A; Roostaei T; Sadaghiani S; Chakravarty MM; Eberly S; Lang AE; Voineskos AN
Ann Neurol; 2015 Nov; 78(5):731-41. PubMed ID: 26284320
[TBL] [Abstract][Full Text] [Related]
6. In vivo imaging of neuromelanin in Parkinson's disease using 18F-AV-1451 PET.
Hansen AK; Knudsen K; Lillethorup TP; Landau AM; Parbo P; Fedorova T; Audrain H; Bender D; Østergaard K; Brooks DJ; Borghammer P
Brain; 2016 Jul; 139(Pt 7):2039-49. PubMed ID: 27190023
[TBL] [Abstract][Full Text] [Related]
7. Serum NFL levels predict progression of motor impairment and reduction in putamen dopamine transporter binding ratios in de novo Parkinson's disease: An 8-year longitudinal study.
Ye R; Locascio JJ; Goodheart AE; Quan M; Zhang B; Gomperts SN
Parkinsonism Relat Disord; 2021 Apr; 85():11-16. PubMed ID: 33639572
[TBL] [Abstract][Full Text] [Related]
8. Impact of disclosure of individual imaging results in a multi-center Parkinson clinical trial.
Jennings D; Eberly S; Oakes D; Seibyl J; Marek K; Shoulson I;
J Parkinsons Dis; 2014; 4(4):629-38. PubMed ID: 25062961
[TBL] [Abstract][Full Text] [Related]
9. Dopamine Transporter Imaging has no Impact on Functional Outcomes in de Novo Probable Parkinson's Disease.
Hickey PT; Kuchibhatla M; Scott B; Gauger L; Stacy MA
J Parkinsons Dis; 2017; 7(2):279-287. PubMed ID: 28339403
[TBL] [Abstract][Full Text] [Related]
10. Longitudinal Change of Clinical and Biological Measures in Early Parkinson's Disease: Parkinson's Progression Markers Initiative Cohort.
Simuni T; Siderowf A; Lasch S; Coffey CS; Caspell-Garcia C; Jennings D; Tanner CM; Trojanowski JQ; Shaw LM; Seibyl J; Schuff N; Singleton A; Kieburtz K; Toga AW; Mollenhauer B; Galasko D; Chahine LM; Weintraub D; Foroud T; Tosun D; Poston K; Arnedo V; Frasier M; Sherer T; Chowdhury S; Marek K;
Mov Disord; 2018 May; 33(5):771-782. PubMed ID: 29572948
[TBL] [Abstract][Full Text] [Related]
11. Progression marker of Parkinson's disease: a 4-year multi-site imaging study.
Burciu RG; Ofori E; Archer DB; Wu SS; Pasternak O; McFarland NR; Okun MS; Vaillancourt DE
Brain; 2017 Aug; 140(8):2183-2192. PubMed ID: 28899020
[TBL] [Abstract][Full Text] [Related]
12. Longitudinal follow-up of SWEDD subjects in the PRECEPT Study.
Marek K; Seibyl J; Eberly S; Oakes D; Shoulson I; Lang AE; Hyson C; Jennings D;
Neurology; 2014 May; 82(20):1791-7. PubMed ID: 24759846
[TBL] [Abstract][Full Text] [Related]
13. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression.
Parkinson Study Group
JAMA; 2002 Apr; 287(13):1653-61. PubMed ID: 11926889
[TBL] [Abstract][Full Text] [Related]
14. Longitudinal evolution of compensatory changes in striatal dopamine processing in Parkinson's disease.
Nandhagopal R; Kuramoto L; Schulzer M; Mak E; Cragg J; McKenzie J; McCormick S; Ruth TJ; Sossi V; de la Fuente-Fernandez R; Stoessl AJ
Brain; 2011 Nov; 134(Pt 11):3290-8. PubMed ID: 22075521
[TBL] [Abstract][Full Text] [Related]
15. Dopamine reuptake transporter-single-photon emission computed tomography and transcranial sonography as imaging markers of prediagnostic Parkinson's disease.
Noyce AJ; Dickson J; Rees RN; Bestwick JP; Isaias IU; Politis M; Giovannoni G; Warner TT; Lees AJ; Schrag A
Mov Disord; 2018 Mar; 33(3):478-482. PubMed ID: 29380907
[TBL] [Abstract][Full Text] [Related]
16. Left hemispheric predominance of nigrostriatal dysfunction in Parkinson's disease.
Scherfler C; Seppi K; Mair KJ; Donnemiller E; Virgolini I; Wenning GK; Poewe W
Brain; 2012 Nov; 135(Pt 11):3348-54. PubMed ID: 23043142
[TBL] [Abstract][Full Text] [Related]
17. Can early dopamine transporter imaging serve as a predictor of Parkinson's disease progression and late motor complications?
Djaldetti R; Rigbi A; Greenbaum L; Reiner J; Lorberboym M
J Neurol Sci; 2018 Jul; 390():255-260. PubMed ID: 29801899
[TBL] [Abstract][Full Text] [Related]
18. Dopamine transporter imaging in autopsy-confirmed Parkinson's disease and multiple system atrophy.
Perju-Dumbrava LD; Kovacs GG; Pirker S; Jellinger K; Hoffmann M; Asenbaum S; Pirker W
Mov Disord; 2012 Jan; 27(1):65-71. PubMed ID: 22102521
[TBL] [Abstract][Full Text] [Related]
19. Precise Evaluation of Striatal Oxidative Stress Corrected for Severity of Dopaminergic Neuronal Degeneration in Patients with Parkinson's Disease: A Study with 62Cu-ATSM PET and 123I-FP-CIT SPECT.
Neishi H; Ikawa M; Okazawa H; Tsujikawa T; Arishima H; Kikuta KI; Yoneda M
Eur Neurol; 2017; 78(3-4):161-168. PubMed ID: 28848099
[TBL] [Abstract][Full Text] [Related]
20. Revision of Diagnosis in Early Parkinsonism with Abnormal Dopamine Transporter Imaging.
Massa J; Chahine LM
J Parkinsons Dis; 2019; 9(2):327-334. PubMed ID: 30958313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
